Exelixis, Inc.
EXEL
#1516
Rank
$14.170 B
Marketcap
United States
Country
$56.37
Share price
1.81%
Change (1 day)
41.56%
Change (1 year)
Categories
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its…
Key Metrics
Trailing P/E
18.53
Forward P/E
13.82
EPS (TTM)
$3.02
Forward EPS
$4.05
Price / Book
7.34
EV / EBITDA
13.4x
Beta
0.42
Dividend Yield
—
Return on Equity
40.99%
Return on Assets
22.03%
Debt / Equity
8.76
Current Ratio
3.26
Gross Margin
96.44%
Operating Margin
41.15%
Net Profit Margin
35.08%
Free Cash Flow
$629.119M
Charts
Price history and financial performance over time.
Price & Market Cap
Jul 6 – Aug 4
+0.80%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$2.320B
Latest Net Income$782.570M
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Exelixis, Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
EXEL
No recent news available. Set FINNHUB_API_KEY to enable news.
